Trial data from AstraZeneca on Friday raised the prospect of a new treatment to prevent COVID-19 beyond vaccines, giving hope in particular for people who respond poorly to immunisation shots.
-
The company said that 75% of the participants in the trial for the therapy - which comprises two types of antibodies discovered by Vanderbilt University Medical Center in the United States - had chronic conditions including some with a lower immune response to vaccinations. Penny Ward, Visiting Professor in Pharmaceutical Medicine at Kings College in London, said the news bode well for people who have responded poorly to vaccination or who must take immune-suppressants for post-transplant, autoimmune disease and other conditions.
"We’re really trying to help patients that need an added level of protection on top of a vaccine," said Pangalos. Another leading AstraZeneca executive, Ruud Dobber, had said last month that different strategic options were being explored for AstraZeneca's vaccine operations, which have faced a string of challenges.The Anglo-Swedish drugmaker has suffered production problems during the rollout of Vaxzevria while very rare cases of blood clotting have weighed heavily on demand for the shot in Europe. The vaccine has also yet to win clearance in the United States.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
AstraZeneca Antibody Drug Found to Prevent Symptomatic Covid-19 in TrialThe company said it would seek regulatory approval after a study showed strong efficacy in preventing symptomatic Covid-19, offering a potential alternative to vaccines for people who refuse shots or for whom they aren’t effective.
Consulte Mais informação »
AstraZeneca says prospect of COVID-19 drug success underscores value of vaccine opsAn AstraZeneca executive said the prospect of offering a new treatment to prevent COVID-19 could position the British drugmaker as a supplier of both vaccines and drugs which guard against the infectious disease.
Consulte Mais informação »
Welcome! You are invited to join a meeting: Conversaciones Comunitarias de COVID-19 y la Vacuna de COVID-19 | Community Conversations about COVID-19 and the COVID-19 Vaccine. After registering, you will receive a confirmation email about joining the meeting.
Consulte Mais informação »
AstraZeneca’s Covid-19 Antibody Therapy Effective In Preventing Symptoms Among High-Risk Groups, Trial FindsAstraZeneca’s treatment may offer additional protection to vulnerable groups who fail to generate a strong immune response through vaccines.
Consulte Mais informação »
Texas health officials warn of full ICUs as state grapples with worsening Covid-19 surgeTexas health officials say the state is in 'one of its worst fights' as Covid-19 hospitalizations rise and leaders and local districts defy safety measures
Consulte Mais informação »